Final Analysis of the Phase 2 Apec Study: Overall Survival (os) Data and Biomarker Subanalyses for First-Line Folfox or Folfiri with Cetuximab (cet) Once Every 2 Weeks in Patients (pts) with Kras or Ras (kras and Nras, Exons 2-4) Wild-Type (wt) Metastatic Colorectal Cancer (Mcrc).
JOURNAL OF CLINICAL ONCOLOGY(2015)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要